Flexion Therapeutics (FLXN) Reaches $24.05 After 8.00% Down Move; Sharpspring (SHSP) Shorts Down By 18.12%

September 1, 2017 - By Dolores Ford

Sharpspring Incorporated (NASDAQ:SHSP) had a decrease of 18.12% in short interest. SHSP’s SI was 46,100 shares in September as released by FINRA. Its down 18.12% from 56,300 shares previously. With 18,000 avg volume, 3 days are for Sharpspring Incorporated (NASDAQ:SHSP)’s short sellers to cover SHSP’s short positions. The SI to Sharpspring Incorporated’s float is 1.1%. About 100 shares traded. SharpSpring Inc (NASDAQ:SHSP) has declined 5.56% since September 1, 2016 and is downtrending. It has underperformed by 22.26% the S&P500.

The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) is a huge mover today! About 295,756 shares traded. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 82.02% since September 1, 2016 and is uptrending. It has outperformed by 65.32% the S&P500.The move comes after 7 months negative chart setup for the $767.33 million company. It was reported on Sep, 1 by Barchart.com. We have $22.13 PT which if reached, will make NASDAQ:FLXN worth $61.39M less.

Investors sentiment increased to 1.74 in 2016 Q4. Its up 0.55, from 1.19 in 2016Q3. It is positive, as 8 investors sold Flexion Therapeutics Inc shares while 16 reduced holdings. 19 funds opened positions while 42 raised stakes. 21.98 million shares or 21.15% more from 18.14 million shares in 2016Q3 were reported. Wasatch Advisors invested in 0.26% or 919,035 shares. Quantbot Lp has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN). Keybank National Association Oh reported 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Gilder Gagnon Howe & Ltd Liability Corp stated it has 1.64% in Flexion Therapeutics Inc (NASDAQ:FLXN). Bamco New York has 0.01% invested in Flexion Therapeutics Inc (NASDAQ:FLXN). National Bank & Trust Of America De owns 16,163 shares for 0% of their portfolio. Tower Research Capital Lc (Trc) accumulated 0.01% or 3,702 shares. Geode Management Lc holds 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN) for 187,039 shares. The California-based Blackrock Institutional Tru Na has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN). Thompson Davis invested in 125 shares. Credit Suisse Ag holds 0% or 18,229 shares in its portfolio. Royal Comml Bank Of Canada accumulated 265,055 shares. Bridgeway Capital has 0.01% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 32,000 shares. Us Natl Bank De invested in 0% or 131 shares. Manufacturers Life Insurance Com The reported 18,140 shares.

Flexion Therapeutics, Inc. is a United States specialty pharmaceutical company. The company has market cap of $767.33 million. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis , a type of degenerative arthritis. It currently has negative earnings. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Among 9 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Flexion Therapeutics had 12 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating by RBC Capital Markets given on Friday, July 7. The rating was initiated by Cantor Fitzgerald on Wednesday, November 4 with “Buy”. The rating was initiated by BMO Capital Markets on Wednesday, June 29 with “Outperform”. The rating was maintained by BMO Capital Markets with “Buy” on Monday, June 26. As per Thursday, July 21, the company rating was initiated by Lake Street. On Tuesday, May 3 the stock rating was reinitiated by Wells Fargo with “Outperform”. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, June 12. Needham maintained it with “Buy” rating and $28.0 target in Wednesday, September 9 report.

Since March 17, 2017, it had 3 insider buys, and 3 sales for $102,399 activity. 5,000 shares were sold by Bodick Neil, worth $102,039 on Friday, March 17. $26,888 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) was bought by Stejbach Mark on Friday, June 16. COLELLA SAMUEL D had bought 5,000 shares worth $85,048. Clayman Michael D. bought 5,000 shares worth $86,152. Another trade for 3,000 shares valued at $69,000 was sold by DRISCOLL FREDERICK W.